Rainbow Children's Medicare Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Rainbow Children's Medicare Ltd filed with BSE on 04 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Rainbow Children's Medicare reported Q1 FY27 revenue of Rs 470 crore, up 33% year-on-year, and EBITDA of Rs 134.6 crore, up 30% year-on-year, with a margin of 28.6%. Management announced new expansion agreements including a 100-bed hospital in Malad, Mumbai, a 70-bed acquisition in Nellore, and a 50-bed lease in Guntur, alongside a five-year plan to add 2,500 beds via roughly Rs 2,200 crore of capex. Management also discussed occupancy, ARPOB and payor mix trends, and outlined progress on hospitals under development in Indore, Coimbatore, Gurgaon, Pune and Bangalore.
Numbers mentioned
Revenue: INR470 crores (Q1 FY27)
p. 6
“Our operating revenue is INR470 crores, reflecting a robust 33% year-on-year growth, driven by healthy contribution from both our mature, acquired and newly commissioned hospitals.”
Vikas Maheshwari, page 6 of the filed PDF · View the filing
EBITDA: INR134.6 crores (Q1 FY27)
p. 6
“Our EBITDA for the quarter amounted to INR134.6 crores, registering a 30% year-on-year growth despite the initial rating losses at the newly commissioned hospitals.”
Vikas Maheshwari, page 6 of the filed PDF · View the filing
EBITDA margin: 28.6% (Q1 FY27)
p. 6
“We maintained a healthy EBITDA margin of 28.6%.”
Vikas Maheshwari, page 6 of the filed PDF · View the filing
Profit after tax: INR62.5 crores (Q1 FY27)
p. 6
“Our profit after tax for the quarter stood at INR62.5 crores, reflecting a 16% year-on-year growth.”
Vikas Maheshwari, page 6 of the filed PDF · View the filing
Cash, cash equivalents and investments: INR613 crores (as of June 30, 2026)
p. 7
“The company continues to maintain a strong balance sheet and healthy liquidity with cash, cash equivalents and the investments stand at INR613 crores as of June 30, 2026.”
Vikas Maheshwari, page 7 of the filed PDF · View the filing
Capital expenditure: approximately INR56 crores (Q1 FY27)
p. 7
“During the quarter, we invested approximately INR56 crores towards capital expenditure, primary focused on expanding and strengthening capabilities across our existing hospitals and upcoming projects in line with our long-term growth strategy.”
Vikas Maheshwari, page 7 of the filed PDF · View the filing
Total bed capacity growth: 26% to 2,435 beds (year-on-year)
p. 5
“Over the past year, our total bed capacity has grown by 26% to 2,435 beds, while our operational bed capacity has increased by 22% to 1,862 beds.”
Abrarali Dalal, page 5 of the filed PDF · View the filing
Occupancy: over 41% (Q1 FY27)
p. 5
“Occupancy improved to over 41%, inpatient discharges by 28%, outpatient consultations by 25% and deliveries by 23%.”
Abrarali Dalal, page 5 of the filed PDF · View the filing
ARPOB improvement: 6% (Q1 FY27)
p. 5
“We also delivered a 6% improvement in ARPOB while maintaining an efficient average length of stay.”
Abrarali Dalal, page 5 of the filed PDF · View the filing
Cash and insurance payor mix: 48% and 42% (Q1 FY27)
p. 7
“Cash and insurance contributed approximately 48% and 42%, respectively, and remained consistent as in the past quarters.”
Vikas Maheshwari, page 7 of the filed PDF · View the filing
ARPOB for hospitals less than five years old: approximately INR 59,000 (Q1 FY27)
p. 12
“For the first quarter, ARPOB for hospitals that are less than five years old was approximately INR 59,000, whereas mature hospitals generated an ARPOB of around INR 70,000—an increase of roughly 18%.”
Vikas Maheshwari, page 12 of the filed PDF · View the filing
Revenue from acquisitions: approximately INR 38 crore (Q1 FY27)
p. 19
“The acquisitions contributed approximately INR 38 crore of revenue during the quarter.”
Vikas Maheshwari, page 19 of the filed PDF · View the filing
Like-to-like revenue growth excluding acquisitions: 24% (Q1 FY27)
p. 19
“So on the revenue growth, Anshul, if you remove this, 24% growth on a like-to-like basis.”
Saurabh Bhandari, page 19 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 20% range · Q2 FY27
stated firmly by Abrarali Dalal
p. 9
“we remain confident of delivering revenue growth in the 20% range during the second quarter as well. We expect growth to remain above 20%.”
Abrarali Dalal, page 9 of the filed PDF · View the filing
Revenue — cross INR 2,000 crores · end of this financial year
stated as an aspiration by Ramesh Kancharla
p. 11
“Based on our current trajectory, we expect to cross INR 2,000 crores in revenue by the end of this financial year.”
Ramesh Kancharla, page 11 of the filed PDF · View the filing
Revenue — double revenue · next four years
stated as an aspiration by Ramesh Kancharla
p. 11
“Looking ahead, over the following four years, we believe we have the potential to double that revenue.”
Ramesh Kancharla, page 11 of the filed PDF · View the filing
Revenue growth — 20% · medium term
stated as an aspiration by Ramesh Kancharla
p. 16
“Yes. If we are able to sustain revenue growth of around 20% annually, that would naturally result in the business doubling its revenue over approximately four years.”
Ramesh Kancharla, page 16 of the filed PDF · View the filing
EBITDA margin — 24%–25% range on a pre-Ind AS basis · by the end of the year
stated firmly by Ramesh Kancharla
p. 14
“We continue to expect EBITDA margins to return to the 24%–25% range on a pre-Ind AS basis by the end of the year.”
Ramesh Kancharla, page 14 of the filed PDF · View the filing
New Bengaluru hospitals breakeven — breakeven within 12 to 15 months, all within about 18 months · 12 to 18 months
stated firmly by Ramesh Kancharla
p. 20
“We expect new Bengaluru hospitals to achieve breakeven within 12 to 15 months, although some may reach it slightly earlier and others a little later. Broadly, we expect all of them to break even within about 18 months.”
Ramesh Kancharla, page 20 of the filed PDF · View the filing
Electronic City hospital breakeven — breakeven · next two to three months
stated firmly by Abrarali Dalal
p. 10
“As for our Electronic City hospital in Bangalore, we expect it to reach breakeven over the next two to three months.”
Abrarali Dalal, page 10 of the filed PDF · View the filing
Mumbai (Malad) EBITDA margin — above 20%
stated as an aspiration by Ramesh Kancharla
p. 13
“However, I am confident that EBITDA margins should eventually be above 20%, although it is too early to estimate where they will ultimately stabilize.”
Ramesh Kancharla, page 13 of the filed PDF · View the filing
Bed capacity expansion — 2,500 beds to reach 5,000 beds via INR2,200 crores capex · next 5 years
stated as an aspiration by Ramesh Kancharla
p. 4
“Over next 5 years, we plan to add 2,500 beds to expand our network capacity to 5,000 beds through an estimated capex of investment around INR2,200 crores.”
Ramesh Kancharla, page 4 of the filed PDF · View the filing
Indore hospital commencement — commence operations · Q3 FY27
stated firmly by Ramesh Kancharla
p. 4
“Commence operations in Indore hospital in Q3 FY27.”
Ramesh Kancharla, page 4 of the filed PDF · View the filing
Malad, Mumbai hospital commencement — commence operations · Q1 FY28
stated firmly by Ramesh Kancharla
p. 3
“We expect the hospital to commence operations in Q1 FY28.”
Ramesh Kancharla, page 3 of the filed PDF · View the filing
Nellore Maternal Care Block commencement — commence operations · 6 months
stated firmly by Ramesh Kancharla
p. 3
“along with an additional 30-bed Maternal Care Block expected to commence operations in 6 months' time.”
Ramesh Kancharla, page 3 of the filed PDF · View the filing
Guntur hospital commencement — commence operations · a couple of months
stated firmly by Ramesh Kancharla
p. 4
“and this facility will commence in -- commence operations in a couple of months' time.”
Ramesh Kancharla, page 4 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said they have visibility on about 1,200 beds in execution and are evaluating opportunities in Noida, Central India, Bhubaneswar and Raipur.
Answered by Ramesh Kancharla
Asked by Sanidhya: Given the bed pipeline, will operational beds reach around 2,050+ by end of FY27, and what's the acquisition strategy for North India?
p. 7
“Yes. As I outlined earlier, we currently have visibility on approximately 1,200 beds that are already in various stages of execution.”
Ramesh Kancharla, page 7 of the filed PDF · View the filing
Management guided to revenue growth remaining above 20% in Q2 despite a higher base.
Answered by Abrarali Dalal
Asked by Sanidhya: Should revenue growth continue at mid-20s from next quarter given a higher base?
p. 9
“we remain confident of delivering revenue growth in the 20% range during the second quarter as well. We expect growth to remain above 20%.”
Abrarali Dalal, page 9 of the filed PDF · View the filing
Management said Rajahmundry is at breakeven and Electronic City in Bangalore is expected to reach breakeven soon.
Answered by Saurabh Bhandari
Asked by Prithvi Raj: How is the profitability of new hospitals like Rajahmundry and the new Bangalore hospital?
p. 10
“Rajahmundry is breakeven right now.”
Saurabh Bhandari, page 10 of the filed PDF · View the filing
Management expects to cross INR 2,000 crore in revenue this year and potentially double it over the following four years.
Answered by Ramesh Kancharla
Asked by Bala Murali Krishna: What revenue growth would 2,500 additional beds over 5 years translate to?
p. 11
“Based on our current trajectory, we expect to cross INR 2,000 crores in revenue by the end of this financial year.”
Ramesh Kancharla, page 11 of the filed PDF · View the filing
Management described Mumbai as a premium but higher-cost market, expecting margins eventually above 20% though timing is uncertain.
Answered by Ramesh Kancharla
Asked by Damayanti Kerai: What are the potential challenges in Mumbai and how profitable could it become?
p. 12
“It is undoubtedly a premium market, with higher employee costs, higher doctor costs, and an overall higher cost structure.”
Ramesh Kancharla, page 12 of the filed PDF · View the filing
Management said margins have faced temporary pressure from bed additions but expect margins to strengthen and return to the 24-25% range by year end.
Answered by Ramesh Kancharla
Asked by Damayanti Kerai: How should FY27/FY28 EBITDA margins be viewed given ongoing spend?
p. 14
“Over the last two years, we have added almost 40% of our current bed capacity, and this expansion has naturally created some temporary pressure on margins, which we had also highlighted during our previous earnings call.”
Ramesh Kancharla, page 14 of the filed PDF · View the filing
Management said acquisitions contributed INR 38 crore of revenue, and like-to-like growth excluding this was 24%.
Answered by Vikas Maheshwari
Asked by Anshul Agrawal: Could you strip out inorganic contribution to quarter revenue growth?
p. 19
“The acquisitions contributed approximately INR 38 crore of revenue during the quarter.”
Vikas Maheshwari, page 19 of the filed PDF · View the filing
Management confirmed these hospitals are still in an investment phase and incurring losses, with breakeven expected within 12-18 months.
Answered by Ramesh Kancharla
Asked by Anshul Agrawal: What losses are being incurred at the new Bengaluru units (HRBR, Electronic City)?
p. 20
“The new Bengaluru hospitals—HRBR and Electronic City—are still in the investment phase and therefore continue to incur losses.”
Ramesh Kancharla, page 20 of the filed PDF · View the filing
Management named technology investment and referral ecosystem strengthening as key priorities, and said they see no direct competitor to their integrated model.
Answered by Abrarali Dalal
Asked by Sucrit Patil: What are the top execution priorities and biggest risks in patient demand or competition?
p. 16
“Our immediate focus is on a few key execution priorities. First, while we are working across multiple levers, technology remains a major focus area.”
Abrarali Dalal, page 16 of the filed PDF · View the filing
Management cited integration of acquired hospitals, cost optimization at greenfield sites, and treasury management as key financial priorities.
Answered by Vikas Maheshwari
Asked by Sucrit Patil: What financial risks and measures are being taken on cost, cash flow and balance sheet?
p. 17
“Therefore, our first priority is ensuring seamless integration of acquired hospitals by standardizing systems, processes, and cost structures.”
Vikas Maheshwari, page 17 of the filed PDF · View the filing
Management said building the right clinical team and earning parental trust are the biggest challenges in new markets.
Answered by Ramesh Kancharla
Asked by Bansi Desai: What is the hardest element to replicate when expanding into newer markets?
p. 17
“The biggest challenge is building the right clinical ecosystem by assembling a high-quality medical team.”
Ramesh Kancharla, page 17 of the filed PDF · View the filing
Management said it is too early to comment, noting the monsoon has been delayed.
Answered by Ramesh Kancharla
Asked by Bansi Desai: What is the initial read on seasonality given monsoon deficit?
p. 21
“It is still too early to comment. The monsoon has been delayed, which everyone is aware of, so we will need to wait and see how the season evolves.”
Ramesh Kancharla, page 21 of the filed PDF · View the filing
Risks flagged
Margin pressure from initial ramp-up losses at newly commissioned hospitals
p. 6
“Our EBITDA for the quarter amounted to INR134.6 crores, registering a 30% year-on-year growth despite the initial rating losses at the newly commissioned hospitals.”
Vikas Maheshwari, page 6 of the filed PDF · View the filing
Higher cost structure in the Mumbai market
p. 12
“It is undoubtedly a premium market, with higher employee costs, higher doctor costs, and an overall higher cost structure.”
Ramesh Kancharla, page 12 of the filed PDF · View the filing
Seasonality of disease patterns affecting demand
p. 17
“Seasonality will always remain a factor in children's hospitals because disease patterns naturally fluctuate.”
Ramesh Kancharla, page 17 of the filed PDF · View the filing
Losses continuing at new Bengaluru hospitals during investment phase
p. 20
“The new Bengaluru hospitals—HRBR and Electronic City—are still in the investment phase and therefore continue to incur losses.”
Ramesh Kancharla, page 20 of the filed PDF · View the filing
Availability of specialist doctors constraining growth in the Northeast
p. 18
“The primary challenge in the Northeast is the availability of specialist doctors.”
Ramesh Kancharla, page 18 of the filed PDF · View the filing
Volatility in debt and credit markets affecting treasury management
p. 17
“Given the volatility in debt and credit markets, our focus is on balancing liquidity, capital safety, and treasury yields while maintaining returns in line with industry standards.”
Vikas Maheshwari, page 17 of the filed PDF · View the filing
Uncertainty over reimbursement rates for government-funded healthcare schemes
p. 10
“However, the decision will depend on the reimbursement rates and overall economics.”
Ramesh Kancharla, page 10 of the filed PDF · View the filing
Challenges of operating across multiple diverse geographies
p. 9
“While operating across multiple geographies does present challenges, we are fully cognizant of them and will continue to execute our proven operating model.”
Ramesh Kancharla, page 9 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.